depression

News

AtaiBeckley has been snapped up by Eli Lilly in a massive $3.8bn transaction that shows psychedelic drugs are now firmly in the pharma mainstream.

News

A survey has found that most patients with depression have little hope of being free of their symptoms, and Johnson & Johnson aims to change that.

Patients

One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.

News

Alto Neuroscience has raised $120m that will fund pivotal trials of its recently acquired candidate for treatment-resistant depression.

News

Volunteers with schizophrenia, bipolar, and depression will take part in an NHS study that will use genetic and health data to find new therapies.

News

Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.